DOCSLIB.ORG

Bbm:978-3-319-63040-3/1.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bbm:978-3-319-63040-3/1.Pdf Index A Addiction medicine specialists Abstinence stage, 226, 227 addiction psychiatry, 12 Abstinence syndrome, 36, 62, 67, 68, 92, 93, 145, ASAM, 12 158, 159 Adolescence, 300–302 alcohol withdrawal, 50 accidents, 293 amphetamines, 101 aftercare plan, 303, 304 anabolic steroids, 183 alcoholic hepatitis, 298 barbiturates assessment, 295 detoxification, 62 behavioral signs and symptoms, 295, 296 symptoms, 62 court order, 298 bath salts, 109 definition, 291 benzodiazepines denial, 294 detoxification, 68 discharge planning, 303 high dose, short half-life, short duration of use, 67 drugs, 293, 294 long half-life, long duration of use, 67 drugs usage, 293, 296 low dose, long duration of use, 67 extended care, 303 rebound phenomenon, 67 family history, 297 symptom reemergence, 67 homicide, 293 caffeine, 111 inpatient treatment, 299, 302 cocaine, 107 medical assessment, 299 detoxification outpatient treatment, 303 buprenorphine (subutex), 92, 93 peer affiliation and acceptance, 292, 304 clonidine, 93 physical examination, 297 methadone, 93 physical growth and sexual maturation, 292 flunitrazepam (Rohypnol), 70 prefrontal cortex, 291 GHB, 72 prevalence, 292, 293 indications, 51, 52 psychological assessment, 300 methylphenidate (ritalin), 108 psychosocial assessment, 296, 297 opioid withdrawal, 92 rehabilitation process outpatient treatment, 50, 51 coping skills and relaxation therapy, 301 outpatient vs. inpatient detoxification, education, 300 52–53 group therapy, 300 phentermine, 109 individual therapy, 300 physical and physiologic changes, 9 life story, 301 rapid detoxification, 93–94 peer assessment, 301 severity, 9 recreational therapy, 301 stage 1, 49 spirituality, 301 stage 2, 49 support group attendance, 301 stage 3, 49 residential treatment, 303 symptoms, 92 screening questionnaire, 296 treatment, 50–53 sexually transmitted diseases, 298 Z drugs, 71 social assessment, 300 Acamprosate (campral), 237, 315 substance dependence, 294 Acute convulsions, 60 substance users, 298 © Springer International Publishing AG 2018 341 H.T. Milhorn, Substance Use Disorders, DOI 10.1007/978-3-319-63040-3 342 Index Adolescence (cont.) neurological system, 47 teenage, 291 nose, 47 tough love and intervention, confrontation, 298 nutritional system, 47, 48 treatment recovery, 53 codependency, 302 reproductive system, 47 family therapy, 302 throat, 47 family week, 302 tolerance, 49 plan development, 300 treatment, 42 support group attendance, 302 type I alcoholism, 46 typical activity schedule, 302 type II alcoholism, 46 urine drug screen, 298 young adult subtype, 46 Adult children of alcoholics (ACOAs), 228, 267 young antisocial subtype, 46 consequences, 267 Alcoholic beverages, 41–42 dysfunctional characteristics, 267, 268 Alcoholic dementia, 310 laundry list, 268, 269 Alcoholic family, rules, 258 support groups, 269 Alcoholics Anonymous (AA), 10, 299 Aerosols, 157, 159, 160 history, 232 adolescent males, 156 meetings, 234, 235 clinical presentation, 159 philosophy, 232 hazardous chemicals, 157, 158 slogans, 233 health risks, 157, 158 12 steps, 232, 233 overdose 12 traditions, 234 azotemia, 160 Alcoholism cardiopulmonary monitoring, 160 direct alcohol biomarkers, 198 chest radiography, 160 indirect alcohol biomarkers, 198–201 chronic gasoline sniffing, 160 physical examination, 195–197 ECG, 160 self-administered questionnaires, hyaline casts, 160 191–193 serum chemistry, 160 Alcohol Use Disorders Identification Test (AUDIT), symptoms, 159 191–193 toluene, 160 Aldehyde dehydrogenase (ALDH), 44 treatment, 160 Alkyl nitrites pharmacology, 156, 157 amyl nitrite, 162 symptoms, 157 butyl nitrite, 162 Affinity, 31 cyclohexyl nitrite, 162 African Americans, 319, 320 health risks, 163 Aftercare, 288–289 overdose, 163–164 follow-up care, 221 pharmacology, 162, 163 Alcohol, 277, 278 street names, 162 Alcohol dehydrogenase (ADH), 44 Alpha-PVP. See Alpha-pyrrolidinovalerophenone Alcohol dependence, 236–237 (alpha-PVP) alcohol-related deaths, 42 Alpha-pyrrolidinovalerophenone alcohol-related liver problems, 42 (alpha-PVP), 110 cancer, 48 Alternative drugs cardiovascular complications, 47 clenbuterol, 184 chronic severe subtype, 46 creatine, 184 dermatological system, 48 EPO, 184 drinking, 42 GHB, 184 drinking and heavy drinking, 42 hCG, 184 ears, 47 HGH, 184 endocrine system, 47 insulin, 184 evaluation, 48, 49 insulin-like growth factor, 184 eyes, 47 vitamins and amino acids, 184 functional subtype, 46 American Indians/Alaska Natives, 318 gastrointestinal manifestations, 47 American Medical Association (AMA), 22, 335, 336 head, 47 American Medical Association’s Council on Mental health benefits, 48 Health, 331, 339 intermediate familial subtype, 46 American Society of Addiction Medicine (ASAM) metabolic disturbances, 47 criteria, 12, 22, 215 musculoskeletal effects, 47 American’s hidden problem, 310 Index 343 Amobarbital (Amytal), Schedule III drugs, 60 B Amotivational syndrome, 136 Bagging, 156 Amphetamine-related hallucinogens, 167, 171–173 Barbiturate-like drugs Amphetamines, 101, 102 ethchlorvynol (placidyl), 73 abstinence syndrome, 101 ethinamate (valmid), 73 acidifying agents, 99 glutethimide (doriden), 73 DEA Schedule II drugs, 98 methaqualone (quaalude), 73 dependence, 101 methyprylon (noludar), 74 market drugs, 98 Barbiturates methamphetamine, 99, 100 abstinence syndrome, 62 overdose abused street names, 60 symptoms, 101 acute convulsions, 60 treatment, 101–102 central nervous system depressants, 59 pharmacodynamics, 98 cluster and migraine headache treatment, 60 pharmacokinetics, 98, 99 CNS depressant drugs, 61 physically and psychologically addictive, 97 defined, 62 prevalence of use, 98 dispositional tolerance, 62 short-term and long-term health effects, 101 enhanced urinary elimination, 63 street names, 98 gastrointestinal decontamination, 63 sympathomimetic preparations, 99 general anesthesia induction, 60 tolerance, 101 health risks, 61–62 Anabolic steroids, 180, 181, 183 hepatic microenzymes, 61 abstinence syndrome, 183 intracranial pressure reduction, 60 adverse consequences, both sexes, lethal injection, 60 182, 183 medical and psychiatric treatment, 59 adverse effects, males and females, 182 overdose, 62, 63 alternative drugs (see Alternative drugs) pharmacodynamics, 61 anabolic-androgenic steroids, 179 pharmacokinetics, 61 denial, 183 pill form, 60 on drug screens, 183, 184 preanesthetic agent, 60 effects, 181, 182 prevalence of use, 59 healthy males, 179 sedation, 60 illegal use seizures treatment, 61 cycling, 181 sleep induction (hypnosis), 61 pyramiding, 181 supportive care, 63 stacking, 181 types of, 60 legal use Bath salts bone marrow problems, 180 abstinence syndrome, 109 chronic wasting conditions, 181 brand names, 109 delayed puberty in male, 180 cheap substitutes, 109 gender dysphoria, 180 DEA Schedule I substances, 109 growth stimulation, 180 health risks, 109 testosterone deficiency, 181 synthetic stimulants, 109 long-term, 183 tolerance and dependence, 109 pharmacology, 182 Behavioral treatment, 213 prevalence of use, 179, 180 Beneficial effect, 48, 56 receptors downregulation, 182 Benzodiazepines, 313, 315 smuggling, 179 abstinence syndrome, 67, 68 street names, 182 central nervous system depression, 65 tablet and injectable forms, 180 class of psychoactive drugs, 64 Antidiarrheal medications cognitive impairment, 66 diphenoxylate HCl/atropine (lomotil), 86 DEA Schedule IV drugs, 64 loperamide (imodium), 86 flunitrazepam (Rohypnol), 6 ASAM. See American Society of Addiction Medicine long-term, health risks, 66 (ASAM) criteria oral contraceptives, antifungal agents and Asian/Pacific Islanders, 318, 319 antibiotics, 66 Asphyxiation, 158 overdose, 68, 69 Atropine, 173 pharmacodynamics, 64 AUDIT. See Alcohol Use Disorders Identification Test pharmacokinetics, 64–65 (AUDIT) physiologic and psychological dependence, 66 344 Index Benzodiazepines (cont.) Cigarettes street names, 64 benefits, quitting smoking, 118, 119 symptoms of depression, 66 combination pharmacotherapy, 127 tolerance, 66 drugs, 118 treatment use, 64 factors, 118 types, 64, 65 health risks, 118 Biomarkers nicotine, 116 direct alcohol, 198 pharmacodynamics, 117 indirect alcohol, 198–201 pharmacokinetics, 117, 118 Biopsychosocial definition, 19 relapse, 127 biological factors, 17–18 smokers, 116–117 psychological view, 18 smoking, 116 sociological factors treatment, 128 family problems, 19 weight gain, 127 financial problems, 19 Civil commitments, 211 isolation, 19 Clenbuterol, 184 legal problems, 19 Clonidine, 93, 126 Blood alcohol concentrations (BACs), 44 Club drugs, 5 Blood alcohol level (BAL), 43, 44, 48 CMRO. See Certified Medical Review Officer (CMRO) Blood-brain barrier (BBB), 33 CNS stimulants, 97–109 Breast and lung cancer deaths, women, 120 alpha-PVP, 110 Breastfeeding, 288 amphetamines (see Amphetamines) Buprenorphine, 238 (see also Bath salts) (see also Caffeine) buprenex, 87, 88 cocaine (see Cocaine) (see also Methylphenidate subutex, 92, 93 (ritalin)) Bupropion (Zyban), 126 modafinil (provigil), 109 Butane, 162 phentermine (see Phentermine) Butorphanol, 87 prevalence of use, 97, 98 Cocaine abstinence syndrome, 107 C antihypertensive properties, 106 Caffeine, 111, 311 chewing coca leaves, 105 abstinence syndrome, 111 coca leaves, 102–103 food and drink products, 110 coca paste, 103 intoxication, 110–111 cocaine HCl, 103 mood-altering drug, 110 coco paste smoking, 105 overdose crack/freebase, 106 symptoms, 111 DEA Schedule II drug, 102 treatment, 111 dependence, 107 powder, 110 Erythroxylum coca plant, 102 tolerance and dependence, 111 forms, 102, 103
Load more

Recommended publications
  • Evaluation the Clinical Effects of Neuroleptanalgesia During
    AL-Qadisiya Journal of Vet. Med. Sci. Vol. 14 No. 1 2015 Evaluation the clinical effects of neuroleptanalgesia (Remifentanil-Acepromazine, Remifentanil-Xylazine, and Remifentanil-Midazolam) during intubation and some minor surgical operations in dogs Samir Aoda Jaffar Ayad Abed-Al-Jabbar Amin Coll. of Vet. Med. / Univ. of Baghdad email: [email protected] (Received 9 January 2014, Accepted 21 April 2014) Abstract The present study intends to evaluate and compare the clinical effects of neuroleptanalgesia induced by using one of the sedative-opioid or tranquilizer-opioid (neuroleptanalgesia) combinations during intubation and some minor surgical operations in dogs. Twenty seven apparently healthy dogs weighing from (15-20 kg) and aged (2-4 years) were divided into three groups, all animals were premedicated with atropine (0.03 mg/kg BW) IM, after 15 minutes neuroleptanalgesia induced as following: Group 1, giving Acepromazine 1mg/kg BW IM and remifentanil 0.5 μg/kg BW IV. Group 2, giving Xylazine 2mg/kg BW IM and remifentanil 0.5 μg/kg BW IV. Group 3, giving Midazolam 0.2mg/kg BW IM and remifentanil 0.5 μg/kg BW IV), in 10 minutes interval respectively in all groups. The following parameters were used for evaluation during the state of (neuroleptanalgesia), eye reflexes, duration and degree of surgical analgesia, degree of sedation, muscle relaxation, respiratory rate, rectal body temperature, and heart rate and rhythm. The results of the study was characterized by good sedation with minor change in heart and respiratory rates and body temperature with excellent analgesia and muscle relaxation quite enough to performed intubation, docking and declawing in groups one and two and less in quality in third group.
    [Show full text]
  • Restraint and Anesthesia of Uncommon Veterinary Patients Bruce H
    Volume 47 | Issue 1 Article 9 1985 Restraint and Anesthesia of Uncommon Veterinary Patients Bruce H. Garver Iowa State University Larry L. Jackson Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/iowastate_veterinarian Part of the Anesthesia and Analgesia Commons, and the Veterinary Medicine Commons Recommended Citation Garver, Bruce H. and Jackson, Larry L. (1985) "Restraint and Anesthesia of Uncommon Veterinary Patients," Iowa State University Veterinarian: Vol. 47 : Iss. 1 , Article 9. Available at: https://lib.dr.iastate.edu/iowastate_veterinarian/vol47/iss1/9 This Article is brought to you for free and open access by the Journals at Iowa State University Digital Repository. It has been accepted for inclusion in Iowa State University Veterinarian by an authorized editor of Iowa State University Digital Repository. For more information, please contact [email protected]. Restraint and Anesthesia of Uncommon Veterinary Patients Bruce H. Garver, BS* Larry L. Jackson, DVM, MS, DACVA** Inttbduction Anesthesia The presentation of small mammals, birds, The variations in anatomical features, size, and reptiles as patients can create consider­ percent body-fat, metabolism, drug sensitivi­ able problems for the veterinarian. Oftenti­ ties, and pre-anesthetic health of the animal mes the veterinarian feels uncomfortable han­ must be considered when anesthesia is to be dling uncommon pets for fear of injury to the administered. Ambient temperature is an im­ pet or clinic staff. This often sends the veteri­ portant consideration. Many anesthetics alter narian searching through textbooks hoping to the animals thermoregulatory mechanism, find a short and concise section dealing with therefore, it is necessary to keep anesthetized the patient at hand.
    [Show full text]
  • The Practice of Veterinary Anesthesia: Small Animals, Birds, Fish and Reptiles This Page Intentionally Left Blank PVA Guts Layout 1 10/14/13 8:35 AM Page Iii
    PVA_Guts_Layout 1 10/14/13 8:35 AM Page i The Practice of Veterinary Anesthesia: Small Animals, Birds, Fish and Reptiles This page intentionally left blank PVA_Guts_Layout 1 10/14/13 8:35 AM Page iii The Practice of Veterinary Anesthesia: Small Animals, Birds, Fish and Reptiles Donald C. Sawyer, DVM, PhD, DACVA Teton NewMedia Teton NewMedia 90 East Simpson, Suite 110 Jackson, WY 83001 © 2008 by Tenton NewMedia Exclusive worldwide distribution by CRC Press an imprint of Taylor & Francis Group, an Informa business Version Date: 20140128 International Standard Book Number-13: 978-1-4822-4129-7 (eBook - PDF) This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional’s own judgement, their knowledge of the patient’s medical history, relevant manufacturer’s instructions and the appropriate best practice guide- lines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the drug companies’ printed instructions, and their websites, before administering any of the drugs recommended in this book.
    [Show full text]
  • ATIVAN (Lorazepam) Injection, USP)
    ATIVAN (lorazepam) injection, USP) For intravenous and intramuscular use NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation (see WARNINGS and PRECAUTIONS, Drug Interactions). DESCRIPTION Lorazepam, a benzodiazepine with antianxiety, sedative, and anticonvulsant effects, is intended for the intramuscular or intravenous routes of administration. It has the chemical formula: 7-chloro-5(2­ chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1, 4-benzodiazepin-2-one. The molecular weight is 321.16, and the C.A.S. No. is [846-49-1]. The structural formula is: Lorazepam is a nearly white powder almost insoluble in water. Each mL of sterile injection contains either 2.0 or 4.0 mg of lorazepam, 0.18 mL polyethylene glycol 400 in propylene glycol with 2.0% benzyl alcohol as preservative. CLINICAL PHARMACOLOGY Lorazepam interacts with the γ-aminobutyric acid (GABA)-benzodiazepine receptor complex, which is widespread in the brain of humans as well as other species. This interaction is presumed to be responsible for lorazepam’s mechanism of action. Lorazepam exhibits relatively high and specific affinity for its recognition site but does not displace GABA. Attachment to the specific binding site enhances the affinity of GABA for its receptor site on the same receptor complex. The pharmacodynamic consequences of benzodiazepine agonist actions include antianxiety effects, sedation, and reduction of seizure activity. The intensity of action is directly related to the degree of benzodiazepine receptor occupancy.
    [Show full text]
  • Dr. ADARSH KUMAR PREMEDICATION (Preanesthetics): A
    PREANAESTHETICS -ANTICHOLINERGICS, SEDATIVES, TRANQUILIZERS Dr. ADARSH KUMAR PREMEDICATION (Preanesthetics): A. General use 1. Sedation of intractable animals for routine diagnostic procedures, examination, trailering etc. 2. Sedation for minor surgical procedures in conjunction with local anaesthesia. 3. Preanesthetic medication: a. Reduces anxiety and improves induction quality. b. Decreases amount of induction agent needed. c. Lengthens and promotes smoother recovery from anaesthesia. d. Decreases the minimum alveolar concentration for inhalation agents e. Decrease salivary and bronchial secretions f. Block vagal reflexes, which can cause bradyarrhythmias. g. Provide pre-, intra-, and immediate post-operative analgesia. Administration of premedicant drugs: a) They are usually given IM 30-40 minutes before induction. (The time will depend on the drugs used.) b) They can be given intravenously to quieten patients. This may be faster acting and have a more profound effect. c) Occasionally, the drugs are given orally. The patient may be extremely difficult to handle (drug is hidden in food or water)Dr. or the dr ugAdarsh may be better absorbed by this route. d) The patient must be left quiet for the drugs to have their full effect. PREMEDICANT DRUGS: A) Anticholinergic Agents : o `Drying' agents which also block vagal tone 1) Naturally found. e.g. atropine. 2) Synthetic. e.g. glycopyrrolate. B) Tranquilizers, or Neuroleptics o These are calming agents which reduce stress. o The animal can arouse from sedation o These drugs have no analgesic properties Dr. Adarsh Page 1 11/6/2007 1 I). Phenothiazine derivatives. e.g. acepromazine II). Butyrophenones. e.g. droperidol, azaperone. III). Benzodiazepines. e.g. diazepam, midazolam.
    [Show full text]
  • Recovery After General Anaesthesia in Adult Horses: a Structured Summary of the Literature
    animals Review Recovery after General Anaesthesia in Adult Horses: A Structured Summary of the Literature Miguel Gozalo-Marcilla 1,* and Simone Katja Ringer 2,* 1 Veterinary Clinical Sciences, Easter Bush Campus, The Royal (Dick) School of Veterinary Studies and The Roslin Institute, The University of Edinburgh, Midlothian EH25 9RG, UK 2 Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zürich, 8057 Zürich, Switzerland * Correspondence: [email protected] (M.G.-M.); [email protected] (S.K.R.); Tel.: +44-(0)-131-651-7366 (M.G.-M.); +41-44-635-84-99 (S.K.R.) Simple Summary: Recovery is the most dangerous phase of general anaesthesia in horses. Numer- ous publications have reported about this phase, but structured reviews that try to reduce the risk of bias of narrative reviews/expert opinions, focussing on the topic are missing. Therefore, the aim of the present article was to publish the first structured review as a summary of the literature focussing on the recovery phase after general anaesthesia in horses. The objective was to summarise the avail- able literature, taking into account the scientific evidence of the individual studies. A structured approach was followed with two experts in the field independently deciding on article inclusion and its level of scientific evidence. A total number of 444 articles, sorted by topics and classified based on their levels of evidence, were finally included into the present summary. The most important findings were summarised and discussed. The present structured review can be used as a compilation of the publications that, to date, focus on the recovery phase after general anaesthesia in adult horses.
    [Show full text]
  • A Practical Discussion of Intravenous Anesthesia
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1936 A practical discussion of intravenous anesthesia Donald E. Carle University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Carle, Donald E., "A practical discussion of intravenous anesthesia" (1936). MD Theses. 427. https://digitalcommons.unmc.edu/mdtheses/427 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. A PRACTICAL DISCUSSION OF INTRAVENOUS ANESTHESIA SENIOR THESIS by DONALD E. CARLE UNIVERSITY of NEBRASKA COLLEGE of MEDICINE APRIL 12, 1936 CONTENTS Page Introduction ------------------------------------- --r History ------------------------------------------ 2-7 Intravenous Route in General 8-12 Ether -------------------------------------------- 13-21 Hedonal ------------------------------------------ 22-28 Somnifaine --------------------------------------- 29-36 Paraldehyde -------------------------------------- 3'7-11 Barbiturates in General 42-48 Amytal ------------------------------------------- 49-59 Pernocton ---------------------------------------- 60-68 Nembutal
    [Show full text]
  • Clonidine in Paediatric Anaesthesia
    From the Department of Surgical Sciences, Section for Paediatric Anaesthesia and Intensive Care, Karolinska Institute, Stockholm, Sweden. Clonidine in paediatric anaesthesia: Pharmacokinetic and pharmacodynamic aspects. Henrik TG Bergendahl Stockholm 2002 Published and printed by Karolinska University Press Box 200, SE-171 77 Stockholm, Sweden © Henrik TG Bergendahl, 2002 ISBN 91-7349-164-0 to my wonderful life companion Birgitta and her fantastic children Johannes and Clara and our beloved children Olle and Anna. - to my parents, my sister and my brothers. - to Professor Allan Ågren. Dissertation quote: “Life is what´s happening to you while you are busy making other plans” John Lennon ABSTRACT Clonidine in paediatric anaesthesia: Pharmacokinetic and pharmacodynamic aspects. Henrik TG Bergendahl. Stockholm 2002. Clonidine is a mixed alpha-2/alpha-1 adrenoceptor agonist. It reduces sympathetic and increases parasympathetic tone which results in a lowering of the baseline blood pressure and heart rate. Descending postjunctional noradrenergic antinociceptive pathways originating in the brainstem are believed to contribute to pain control of both nociceptive and neuropathic origin after clonidine challenge. The sedative effect of clonidine is due to alpha-2 adrenoceptor stimulation in the locus coeruleus. In adults, oral clonidine provides preoperative sedation, increases perioperative haemodynamic stability, reduces the requirements of volatile anaesthetic requirements, and attenuates the stress response secondary to intubation. A pure analgesic effect is seen after both systemic and neuraxial administration. In paediatric anaesthesia similar beneficial effects have been observed. To provide safe and effective use of clonidine in children further studies delineating its specific pharmacokinetic and haemodynamic characteristics are needed, despite its recently increased clinical use.
    [Show full text]
  • ANASED- Xylazine Hydrochloride Injection, Solution
    ANASED- xylazine hydrochloride injection, solution Patterson Veterinary ---------- AnaSed® Injection (xylazine injection) 100 mg/mL Sedative and Analgesic for Use in Horses and Cervidae (Fallow Deer, Mule Deer, Sika Deer, White- Tailed Deer and Elk) CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in Cervidae less than 15 days before or during the hunting season. DESCRIPTION: AnaSed® is supplied in 50 mL multiple-dose vials as a sterile solution. EACH mL CONTAINS: Xylazine hydrochloride equivalent to 100 mg of base activity, methylparaben 0.9 mg, propylparaben 0.1 mg, sodium citrate dihydrate 5.0 mg and water for injection. pH adjusted with citric acid and sodium citrate. INDICATIONS: Xylazine should be used in horses and Cervidae (Fallow Deer, Mule Deer, Sika Deer, White-Tailed Deer and Elk) when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. Horses: Xylazine has been used successfully as follows: 1. Diagnostic procedures — oral and ophthalmic examinations, abdominal palpation, rectal palpation, vaginal examination, catheterization of the bladder and radiographic examinations. 2. Orthopedic procedures, such as application of casting materials and splints. 3. Dental procedures. 4. Minor surgical procedures of short duration such as debridement, removal of cutaneous neoplasms and suturing of lacerations. 5. To calm and facilitate handling of fractious animals. Major surgical procedures: a. When used as a preanesthetic to general anesthesia. b. When used in conjunction with local anesthetics. Cervidae: Xylazine may be used for the following: 1. To calm and facilitate handling of fractious animals.
    [Show full text]
  • CCAC Vol2 Non Human Primates
    Guide to the Care and Use of Experimental Animals, Volume 2 (1984) XX. NON-HUMAN PRIMATES Please note that the CCAC Guide to the Care and Use of Experimental Animals, vol. 2 (1984) is out of date and currently under revision. In the interim, sections of this chapter have been replaced by reference to more recent CCAC publications where available. The sections that have not been replaced should be viewed alongside more recent literature, such as that available on the CCAC Three Rs microsite (http://www.ccac.ca/en/alternatives/ species-resources_ressources-especes/primates.html). A. INTRODUCTION Non-human primates are exotic animals requiring special housing and knowledgeable care if they are to be successfully maintained and used in research. Measures to safeguard their psychological stability should take equal precedence to those concerning physical health (McGrew, 1980). Many non-human primate species are threatened with extinction; others are in relatively short supply, difficult to procure and therefore expensive. The stresses of capture and transport predispose these animals to a variety of disease syndromes which often result in a high mortality prior to their arrival at the research facilities. Because non-human primates carry substantial zoonoses that pose a serious potential health hazard to personnel, and because of their susceptibility to a number of human diseases, special precautions must be taken in maintaining these animals. In light of these facts, it is clearly apparent that non-human primates should only be used for research purposes when no other species is suitable for the particular project and all other alternatives have been rejected.
    [Show full text]
  • Chapter 3 T&L
    Chapter 3 Anesthetic Agents and Adjuncts 1 Chapter 3 Anesthetic Agents and Adjuncts Anesthetic agents and adjuncts may be classified a number of ways. First, they may be classified based on the route of administration. Inhalant agents are administered from an anesthetic machine into the lower respiratory tree via an endotracheal tube or mask. Injectable agents are injected intravenously, intramuscularly, subcutaneously, intraperitoneally, intralesionally, or into a number of other locations. Oral agents are given by mouth, and topical agents are applied to a body surface such as the skin or mucous membranes. Another way these agents may be classified is based on the time period at which they are given during the course of an anesthetic procedure. Drugs given before general anesthesia are referred to as preanesthetic medications. Drugs used to induce general anesthesia are referred to as induction agents, and those used to maintain general anesthesia are referred to as maintenance agents. A third way anesthetic agents and adjuncts may be classified is according to the principal effect. Local anesthetics induce a loss of sensation in a localized area of the body. In contrast, general anesthetics induce a loss of sensation over the entire body, accompanied by unconsciousness. Sedatives and tranquilizers are agents that cause sedation and tranquilization, respectively. Analgesics prevent and control pain. Muscle relaxants decrease muscle tone. Chapter 3 Anesthetic Agents and Adjuncts Neuromuscular blockers, although infrequently used in general practice, are used to relax or paralyze skeletal muscles during ophthalmic, orthopedic, or other surgeries. Anticholinergic agents are used to decrease effects of parasympathetic nervous system (PNS) stimulation such as bradycardia and excessive salivation.
    [Show full text]
  • Preanesthesia, Anesthesia, Analgesia, and Euthanasia Paul Flecknell, MA, Vetmb, Phd, DECLAM, DLAS, DECVA, (Hon) DACLAM, (Hon) Frcvsa, Jennifer L.S
    CHAPTER 24 Preanesthesia, Anesthesia, Analgesia, and Euthanasia Paul Flecknell, MA, VetMB, PhD, DECLAM, DLAS, DECVA, (Hon) DACLAM, (Hon) FRCVSa, Jennifer L.S. Lofgren, DVM, MS, DACLAMb, Melissa C. Dyson, DVM, DACLAMb, Robert R. Marini, DVMc, M. Michael Swindle, DVMd and Ronald P. Wilson, VMD, MSe aComparative Biology Medicine, Newcastle University, Newcastle Upon Tyne, UK bUnit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA cDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts dDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC, USA ePenn State College of Medicine, Department of Comparative Medicine, Hershey, PA, USA OUTLINE I. Introduction 1136 IV. Ferrets 1156 A. Introduction 1156 II. Rodents 1136 B. Preoperative Assessment and Preparation 1157 A. Introduction 1136 C. Intraoperative Anesthetics 1158 B. Preoperative Assessment and Preparation 1136 D. Intraoperative Monitoring and Support 1160 C. Anesthetic Agents 1137 E. Postoperative Recovery 1160 D. Intraoperative Monitoring and Support 1143 F. Acute and Chronic Analgesic Therapy 1160 E. Special Anesthetic Considerations 1144 G. Special Anesthetic Considerations 1161 F. Analgesic Therapy 1145 G. Species Considerations 1147 V. Swine 1162 H. Euthanasia 1148 A. Introduction 1162 B. Preoperative Assessment and Preparation 1162 III. Rabbits 1149 C. Intraoperative Anesthesia 1163 A. Introduction 1149 D. Intraoperative Monitoring and Support 1166 B. Preoperative Assessment and Preparation 1149 E. Special Anesthetic Considerations 1166 C. Intraoperative Anesthesia 1150 F. Postoperative Recovery 1167 D. Intraoperative Monitoring and Support 1154 G. Acute and Chronic Analgesic Therapy 1167 E. Special Anesthetic Considerations 1154 H. Euthanasia 1168 F. Acute and Chronic Analgesic Therapy 1155 Laboratory Animal Medicine, Third Edition DOI: http://dx.doi.org/10.1016/B978-0-12-409527-4.00024-9 1135 © 20122015 Elsevier Inc.
    [Show full text]